Titre :

Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.

Auteur(s) :

Hervochon, Charles [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Hennart, Benjamin [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Leroy, Anne-Gaëlle [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Corvec, Stéphane [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Boutoille, David [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Senneville, Eric [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Sotto, Albert [Auteur]
Hôpital Universitaire Carémeau [Nîmes] [CHU Nîmes]
Illes, G. [Auteur]
Chavanet, P. [Auteur]
Dubée, V. [Auteur]
Bleibtreu, A. [Auteur]
De Carné, M. C. [Auteur]
Talarmin, J. P. [Auteur]
Revest, M. [Auteur]
Castan, B. [Auteur]
Bellouard, R. [Auteur]
Dailly, É. [Auteur]
Allorge, Delphine [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Dinh, A. [Auteur]
Le Turnier, P. [Auteur]
Gregoire, M. [Auteur]

Titre de la revue :

Journal of Antimicrobial Chemotherapy

Nom court de la revue :

J Antimicrob Chemother

Numéro :

78

Pagination :

2919–2925

Éditeur :

Oxford Academic

Date de publication :

2023-10-22

ISSN :

1460-2091

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives Limited pharmacokinetics data support dalbavancin long-term use in off-label indications and the optimal dosing regimen is debated. We aimed to describe dalbavancin concentrations in an observational retrospective ...
Lire la suite >Objectives Limited pharmacokinetics data support dalbavancin long-term use in off-label indications and the optimal dosing regimen is debated. We aimed to describe dalbavancin concentrations in an observational retrospective multicentre study. Methods Patients from 13 French hospitals, treated with 1500 mg doses of dalbavancin and for whom therapeutic drug monitoring was performed from June 2018 to March 2021 were included. Dalbavancin plasma concentrations were described at peak and 1, 2, 3, 4, 6 and 8 weeks after the last 1500 mg dose. Concentrations in patients weighing more or less than 75 kg and with a GFR greater or less than 60 mL/min were compared. Microbiological data were collected and dalbavancin MIC was measured when possible. Results One hundred and thirty-three patients were included (69% treated for bone and joint infections, 16% for endocarditis). Thirty-five patients received a single dose of dalbavancin and 98 received several administrations. Two, 3 and 4 weeks after the last dose, median plasma concentrations were respectively 25.00, 14.80 and 9.24 mg/L for the first doses and 34.55, 22.60 and 19.20 mg/L for the second or subsequent doses. Weight and renal function had an impact on pharmacokinetics. Infection was documented in 105 patients (Staphylococcus spp. in 68% of cases). Staphylococcus aureus was isolated in 32.5% of cases (median MIC: 0.047 mg/L) and Staphylococcus epidermidis in 27% of cases (median MIC of 0.047 mg/L). Conclusions Plasma concentrations of dalbavancin were consistent with those described in clinical trials and those sought during the industrial development of the molecule.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
Institut Pasteur de Lille

Collections :

• IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483

Date de dépôt :

2023-11-17T04:19:54Z
2023-12-20T10:43:02Z